Medical Doctor Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Sarah Bou Nader

General Practice Leesburg, FL Medical Doctor

NPI 1356907687 CMS profile 11391353

1801 US Highway 441, Leesburg, FL 34748

Open in the dashboard

General payments

$833

43 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sarah Bou Nader of Leesburg, FL is reported in the CMS Open Payments database as having received $833 across 43 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 77th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $316 16
2024 General $301 16
2023 General $217 11

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sarah Bou Nader
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to Sarah Bou Nader were reported at $316. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year Sarah Bou Nader General Practice median Middle half National median
2019 $0 $107 $37–$285 $163
2020 $0 $75 $25–$213 $114
2021 $0 $93 $30–$272 $132
2022 $0 $103 $36–$279 $149
2023 $217 $106 $34–$276 $160
2024 $301 $114 $39–$290 $164
2025 $316 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Novo Nordisk Inc $223 10 payments
  2. AstraZeneca Pharmaceuticals LP $183 11 payments
  3. GlaxoSmithKline, LLC. $133 7 payments
  4. Exact Sciences Corporation $100 5 payments
  5. Pfizer Inc. $51 3 payments
  6. Astellas Pharma US Inc $39 2 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $28 1 payment
  8. Abbott Laboratories $24 1 payment
  9. Medtronic, Inc. $20 1 payment
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $17 1 payment
  11. Other $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $833 43 payments
Products named General payments · program years 2023–2025
  1. Ozempic $180 8 payments
  2. RYBELSUS $158 7 payments
  3. AIRSUPRA $103 6 payments
  4. Cologuard Collection Kit $100 5 payments
  5. SHINGRIX $82 4 payments
  6. TRELEGY ELLIPTA $51 3 payments
  7. FARXIGA $44 3 payments
  8. Veozah $39 2 payments
  9. BREZTRI $36 2 payments
  10. NURTEC ODT $35 2 payments
  11. Other $257 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 191 drugs

Part D claims

12,755

Median for Family Practice: 1,826

Drug cost

$977,558

Median for Family Practice: $120,094

Branded share of claims

17.5%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 72 $94,857
Eliquis Apixaban Brand 72 $94,282
Genvoya Elviteg/Cob/Emtri/Tenof Alafen Brand 19 $77,620
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 56 $63,412
Trulicity Dulaglutide Brand 35 $56,567
Januvia Sitagliptin Phosphate Brand 40 $52,917
Jardiance Empagliflozin Brand 41 $50,632
Xarelto Rivaroxaban Brand 36 $35,226
Myrbetriq Mirabegron Brand 42 $31,606
Farxiga Dapagliflozin Propanediol Brand 23 $29,557

The 10 drugs with the highest cost, of 191 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 105 billing codes

Paid by Medicare

$103,832

Of which drugs: $14,070

Medicare patients

236

Average age 76

Services billed

6,051

119 women, 117 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 56%
Arthritis 56%
Ischemic heart disease 42%
Diabetes 32%
Depression 32%
COPD 27%
Atrial fibrillation 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90653 Office 21 21 $1,718
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 14 67 $50

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $39
$39 — —
RYBELSUS
  • Novo Nordisk Inc $36
$36 — —
Ozempic
  • Novo Nordisk Inc $36
$36 72 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $33
$33 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $28
$28 41 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

43 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other General Practice in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record